Compare IDEXX Laboratories, Inc. (IDXX) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs SoFi Technologies Inc — how do they compare? IDEXX Laboratories, Inc. trades at $572.36 (market cap $46.22B), while SoFi Technologies Inc trades at $17.93 (market cap $23.22B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| IDXX | SOFI | |
|---|---|---|
Market Cap | $46.22B | $23.22B |
Sector | Health | Financials |
52-Week High | $766.68 | $32.21 |
52-Week Low | $526.44 | $15.15 |
Enterprise Value | $47.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
SoFi Technologies (SOFI) trades at $17.82, down 1.66% on the day, with a bullish technical signal from moving averages despite a neutral RSI. The company reported strong Q2 2026 earnings, beating EPS estimates with 40% year-over-year adjusted net revenue growth and record loan originations. Revenue guidance for 2026 was raised to $4.75-$4.85 billion. The stock's valuation shows a P/E of 36.69 and P/S of 5.6, reflecting growth expectations. Analyst consensus is a 'Buy' with a $19.50 price target, though institutional sentiment is mixed with recent position adjustments.
The outlook for SOFI is positive, driven by robust member growth, cross-selling success, and expanding fee-based revenue. Key risks include dependence on interest rate trends, competitive pressures in digital banking, and execution challenges in scaling the technology platform. The stock presents an opportunity for growth investors, but volatility may persist amid macroeconomic uncertainties and investor sensitivity to guidance updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
